Drug Profile
Research programme: deubiquitinating enzyme inhibitors - Carmot Therapeutics
Latest Information Update: 01 Feb 2024
Price :
$50
*
At a glance
- Originator Carmot Therapeutics
- Class Antineoplastics
- Mechanism of Action Deubiquitinating enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer
Most Recent Events
- 29 Jan 2024 Carmot Therapeutics has been acquired by Roche
- 03 Jul 2023 Discontinued for Autoimmune disorders in USA (unspecified route) (Carmot Therapeutics pipeline, July 2023)
- 03 Jul 2023 Discontinued for Cancer in USA (unspecified route) (Carmot Therapeutics pipeline, July 2023)